News
15 February 2022
Europe
Asthma
- Research Projects

EFA invites you to the CURE conference: “Towards a CURE for Asthma: Accelerating Innovation in Personalised Medicine and Phage Therapies,” which takes place on 15 March 2022, 9:30-12:00 and 13:30-15:20 CET.

EFA participates in several EU-funded projects, to help facilitate patient engagement and dissemination towards patient communities and other stakeholders. The CURE project began in 2017 and will culminate this March with a final scientific conference. 

CURE is an EU Horizon 2020 project designed to explore new approaches to improve the manageability of asthma and the potential of an intervention based on virus (called phage therapy) to address imbalances in the respiratory microbiome contributing to the disease.

As a partner in the research consortium, EFA has led the project communication activities to help inform the public, and in particular people with asthma, about the results of the research conducted within the project. EFA is now organising the final conference and invites you to save the date for a thrilling exploration of project accomplishments and phage adventures in Europe and across the globe.

The event will open with a Member of the European Parliament and a patient representative, speaking on the importance of innovative research and development for allergy and asthma patients.

Project Coordinator Nikolaos Papadopoulos and Horizon Europe Programme Officer, Barbara Gerratana will then present an overview of innovations unique to the CURE project and what we can expect from this novel therapy as the project comes to a close.

Following a short break, there will be two scientific panels exploring phage innovations and best practices from outside the EU, and the legal and regulatory frameworks for future phage applications at the Member State and EU levels.

Mark your calendars and register now.

To know more about this project, visit the CURE website.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 767015.